Form 4: Arcutis CEO Sells Shares Under 10b5-1 Plan

Arcutis Biotherapeutics President and CEO Todd Watanabe sold common stock totaling 50,000 shares in November 2025 under a pre-arranged 10b5-1 trading plan.

Summary

• Todd Watanabe, President and Chief Executive Officer of Arcutis Biotherapeutics, Inc. (ARQT), reported sales of common stock.
• On November 21, 2025, 1,055 shares were sold at a price of $30.00 per share.
• On November 24, 2025, an additional 48,945 shares were sold at a weighted average price of $30.3556 per share, with individual transaction prices ranging from $30.00 to $30.73.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on June 3, 2025, which has a plan end date of September 30, 2026.
• Following these reported transactions, Watanabe directly beneficially owns 740,537 shares of common stock.
• The filing also notes a transfer of shares to an ex-spouse pursuant to a domestic relations order.
• Watanabe also holds indirect beneficial ownership of 233,134 shares through various trusts and an LLC, disclaiming beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine insider stock sales executed under a pre-arranged 10b5-1 trading plan, which is a common practice and does not inherently indicate positive or negative sentiment regarding the company's future prospects. The transfer to an ex-spouse is a personal matter.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Noted insider selling by a key executive, though executed under a pre-arranged 10b5-1 trading plan, which typically mitigates concerns about opportunistic selling.

Key Dates

Recommendation

The filing is a routine Form 4 reporting insider stock sales executed under a pre-arranged 10b5-1 trading plan. Such transactions are typically for personal financial planning, diversification, or liquidity and do not usually signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this disclosure. The transfer of shares to an ex-spouse is a personal matter and not indicative of company performance.

Keywords

Arcutis Biotherapeutics, ARQT, Todd Watanabe, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Officer Transaction, Director Transaction, Biotechnology